Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Early hepatitis B vaccination may be ineffective in teenagers

Research reveals that many infants who receive the complete series of hepatitis B virus vaccinations have lost their protection by the time they reach adolescence.

14 Jan 2013

VolitionRx to commence large internal clinical study for Nucleosomics diagnostic products

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests, announces that it will commence a large internal clinical study for its Nucleosomics diagnostic products this month.

9 Jan 2013

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.

9 Jan 2013

Adolescents may lose hepatitis B virus protection despite vaccination as infants

New research reveals that a significant number of adolescents lose their protection from hepatitis B virus (HBV) infection, despite having received a complete vaccination series as infants. Results in the January 2013 issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, suggest teens with high-risk mothers (those positive for HBeAg) and teens whose immune system fails to remember a previous viral exposure (immunological memory) are behind HBV reinfection.

8 Jan 2013

$Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer$

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.

3 Jan 2013

SVR associated with prolonged overall survival in patients with chronic HCV infection

Among patients with chronic hepatitis C virus infection and advanced hepatic fibrosis (development of excess fibrous connective tissue), sustained virological response (SVR) to interferon-based treatment was associated with a lower risk of all-cause mortality compared with patients without SVR, according to a study in the December 26 issue of JAMA.

26 Dec 2012

UV nail lamp use not associated with skin cancer risk

Research shows that artificial ultraviolet (UV) nail lamps do not significantly increase the risk for developing keratinocyte carcinoma.

22 Dec 2012

New work on Akt's role in cancer stem cell biology

The protein kinase Akt is a key regulator of cell growth, proliferation, metabolism, survival, and death. New work on Akt's role in cancer stem cell biology from the lab of senior author Honglin Zhou, MD, PhD and Weihua Li, co-first author, both from the Center for Resuscitation Sciences, Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, and Xiaowei Xu, Department of Pathology and Laboratory Medicine, appears in Molecular Cell.

21 Dec 2012

Vismodegib team wins Drug Discovery of the Year award

The British Pharmacological Society proudly announces that its first annual Drug Discovery of the Year award has been won by the discovery team developing vismodegib for the treatment of basal cell carcinoma (a type of skin cancer).

19 Dec 2012

Cytokine rise signals RCC progression

Progression of renal cell carcinoma is frequently preceded by a rise in levels of proangiogenic cytokines, Italian researchers have found.

17 Dec 2012

Nephron-sparing surgery beats ablation for small renal masses

Nephron-sparing surgery is more effective than ablation for the treatment of clinical stage T1a renal masses, research findings show.

17 Dec 2012

Preop features predict pathology of small renal masses

Researchers have identified preoperative clinical and tumor characteristics that predict the risk for malignancy in patients undergoing partial nephrectomy for small renal masses.

17 Dec 2012

Partial nephrectomy maintains renal function in cT1a RCC

Partial nephrectomy offers a similar magnitude of benefit in patients with clinical T1b versus cT1a renal cell carcinoma, Japanese researchers have shown.

17 Dec 2012

NeoGenomics launches FISH assay for surveillance of patients with Barrett's Esophagus

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today it has validated and launched a laboratory developed Fluorescent in Situ Hybridization assay for the surveillance of patients with Barrett's Esophagus.

17 Dec 2012

Predictor of lymph node metastasis after oral cancer unmasked

The presence of high levels of tumor-associated tissue eosinophilia in early oral squamous cell carcinoma tissue can predict future occult lymph node metastasis, study results show.

13 Dec 2012

Sirtex unveils new website to learn more about SIR-Spheres microspheres

Sirtex today unveiled a new, comprehensive and easy-to-use global website for doctors, nurses, patients and investors interested in learning more about SIR-Spheres microspheres, a form of radiotherapy targeting liver tumours that is gaining increasingly wide acceptance worldwide.

13 Dec 2012

New diagnostic assay for screening ALK fusions in non-small cell lung carcinoma

Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients are highly responsive to ALK-specific kinase inhibitors such as crizotinib.

From NanoString Technologies 13 Dec 2012

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

New lung cancer loci found

Genome-wide analysis has identified three new susceptibility loci for lung cancer in a large cohort of never-smoking women in Asia.

10 Dec 2012

Baby boomers with liver cancer drive demand for liver transplantation

New research reveals that the greatest demand for liver transplantation due to hepatitis C (HCV)-related liver disease occurs among Americans born between 1941 and 1960. Findings in the December issue of Liver Transplantation, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD), suggest that continuing increased demand for transplantation is driven by the development of liver cancer in baby boomers with HCV, but that the demand may decrease as patients born in this time period continue to grow older.

7 Dec 2012